XML 41 R28.htm IDEA: XBRL DOCUMENT
v3.26.1

Operating Segments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Operating Segments |
Schedule of operating segments | The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the year ended December 31, 2025: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ | Specialized BioTherapeutics | ​ | Public Health Solutions | ​ | Total Segments | ​ | Adjustments | ​ | Corporate | ​ | Adjustments | ​ | Consolidated
Revenues | ​ | $ | - | ​ | $ | - | ​ | $ | - | ​ | $ | - | ​ | $ | - | ​ | $ | - | ​ | $ | -
Cost of revenues | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | -
Gross profit | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | -
Significant expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | ​ | 6,776,867 | ​ | ​ | 86,768 | ​ | ​ | 6,863,635 | ​ | ​ | 207,105 | ​ | ​ | 415,073 | ​ | ​ | - | ​ | ​ | 7,485,813
General and administrative | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | 3,975,961 | ​ | ​ | 383,702 | ​ | ​ | 4,359,663
Adjusted loss from operations | ​ | ​ | (6,776,867) | ​ | ​ | (86,768) | ​ | ​ | (6,863,635) | ​ | ​ | (207,105) | ​ | ​ | (4,391,034) | ​ | ​ | (383,702) | ​ | ​ | (11,845,476)
Share-based compensation | ​ | ​ | 203,169 | ​ | ​ | 1,679 | ​ | ​ | 204,848 | ​ | ​ | (204,848) | ​ | ​ | 382,735 | ​ | ​ | (382,735) | ​ | ​ | -
Depreciation and amortization | ​ | ​ | 1,935 | ​ | ​ | 322 | ​ | ​ | 2,257 | ​ | ​ | (2,257) | ​ | ​ | 967 | ​ | ​ | (967) | ​ | ​ | -
Loss from operations | ​ | ​ | (6,981,971) | ​ | ​ | (88,769) | ​ | ​ | (7,070,740) | ​ | ​ | - | ​ | ​ | (4,774,736) | ​ | ​ | - | ​ | ​ | (11,845,476)
Other income, net | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | 258,481 | ​ | ​ | - | ​ | ​ | 258,481
Net loss before income taxes | ​ | $ | (6,981,971) | ​ | $ | (88,769) | ​ | $ | (7,070,740) | ​ | $ | - | ​ | $ | (4,516,255) | ​ | $ | - | ​ | $ | (11,586,995)
​ ​ The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the year ended December 31, 2024: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ | Specialized BioTherapeutics | ​ | Public Health Solutions | ​ | Total Segments | ​ | Adjustments | ​ | Corporate | ​ | Adjustments | ​ | Consolidated
Revenues | ​ | $ | 119,371 | ​ | $ | - | ​ | $ | 119,371 | ​ | $ | - | ​ | $ | - | ​ | $ | - | ​ | $ | 119,371
Cost of revenues | ​ | ​ | (119,371) | ​ | ​ | - | ​ | ​ | (119,371) | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | (119,371)
Gross profit | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | -
Significant expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | ​ | 4,233,771 | ​ | ​ | 249,852 | ​ | ​ | 4,483,623 | ​ | ​ | 135,987 | ​ | ​ | 603,979 | ​ | ​ | - | ​ | ​ | 5,223,589
General and administrative | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | 4,016,266 | ​ | ​ | 199,642 | ​ | ​ | 4,215,908
Adjusted loss from operations | ​ | ​ | (4,233,771) | ​ | ​ | (249,852) | ​ | ​ | (4,483,623) | ​ | ​ | (135,987) | ​ | ​ | (4,620,245) | ​ | ​ | (199,642) | ​ | ​ | (9,439,497)
Share-based compensation | ​ | ​ | 127,774 | ​ | ​ | 4,143 | ​ | ​ | 131,917 | ​ | ​ | (131,917) | ​ | ​ | 197,898 | ​ | ​ | (197,898) | ​ | ​ | -
Depreciation and amortization | ​ | ​ | 3,489 | ​ | ​ | 581 | ​ | ​ | 4,070 | ​ | ​ | (4,070) | ​ | ​ | 1,744 | ​ | ​ | (1,744) | ​ | ​ | -
Loss from operations | ​ | ​ | (4,365,034) | ​ | ​ | (254,576) | ​ | ​ | (4,619,610) | ​ | ​ | - | ​ | ​ | (4,819,887) | ​ | ​ | - | ​ | ​ | (9,439,497)
Other (expenses) income, net | ​ | ​ | (22,342) | ​ | ​ | - | ​ | ​ | (22,342) | ​ | ​ | - | ​ | ​ | 786,149 | ​ | ​ | - | ​ | ​ | 763,807
Net loss before income taxes | ​ | $ | (4,387,376) | ​ | $ | (254,576) | ​ | $ | (4,641,952) | ​ | $ | - | ​ | $ | (4,033,738) | ​ | $ | - | ​ | $ | (8,675,690)
​ Reconciliation to Consolidated Loss Before Income Taxes The following table provides a reconciliation of total segment loss to consolidated loss before income taxes: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2025 | ​ | 2024
Loss from operations - reportable segments | ​ | $ | (7,070,740) | ​ | $ | (4,619,610)
Loss from operations - corporate | ​ | ​ | (4,774,736) | ​ | ​ | (4,819,887)
Interest income, net | ​ | ​ | 270,170 | ​ | ​ | 213,975
Other income (expense), net | ​ | ​ | (11,689) | ​ | ​ | 549,832
Net loss before income taxes | ​ | $ | (11,586,995) | ​ | $ | (8,675,690)
​ ​ Segment Assets The Company’s total assets by segment as of December 31, 2025, are presented below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Specialized BioTherapeutics | ​ | Public Health Solutions | ​ | Total Segments | ​ | Corporate | ​ | Consolidated
Total assets | ​ | $ | 77,872 | ​ | $ | 2,924 | ​ | $ | 80,796 | ​ | $ | 9,154,725 | ​ | $ | 9,235,521
​ The Company’s total assets by segment as of December 31, 2024, are presented below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Specialized BioTherapeutics | ​ | Public Health Solutions | ​ | Total Segments | ​ | Corporate | ​ | Consolidated
Total assets | ​ | $ | 48,604 | ​ | $ | 2,038 | ​ | $ | 50,642 | ​ | $ | 8,915,841 | ​ | $ | 8,966,483

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration